About 17 results found for searched term "JAK-IN-20" (0.136 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M49602 | JAK-IN-20 | JAK |
| JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC50s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. | ||
| M3535 | Gandotinib | JAK |
| LY2784544 | ||
| Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. | ||
| M4870 | Cerdulatinib | JAK |
| PRT062070, PRT2070 | ||
| Cerdulatinib (PRT-062070, PRT2070) is an orally active multi-target tyrosine kinase inhibitor with IC50s of JAK1/JAK2/JAK3/TYK2 and Syk 12 nM/6 nM/8 nM/0.5 nM and 32 nM, respectively. It was also able to inhibit the other 19 kinases tested, all with IC50 below 200 nM. | ||
| M6297 | Upadacitinib | JAK |
| ABT-494 | ||
| Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research. | ||
| M11186 | NVP-BSK805 | JAK |
| BSK805 | ||
| NVP-BSK805 is a potent, selective, ATP competitive JAK2 inhibitor with an IC50 of 0.5 nM, which is more than 20 times more selective than acting on JAK1, JAK3 and TYK2. | ||
| M28058 | MS-1020 | JAK |
| MS-1020 is a potent and ATP-competitive JAK3 inhibitor. MS-1020 inhibits JAK3/STAT signaling and induces apoptosis. MS-1020 promotes cell death. MS-1020 decreases the expression of tyrosine phosphorylated STAT3 levels. MS-1020 has the potential for the research of cancers harboring aberrant JAK3 signaling. | ||
| M28457 | Ivarmacitinib | JAK |
| SHR0302 | ||
| Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of Ivarmacitinib for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects. | ||
| M30500 | RO8191 | Interferon-α/β/γ |
| CDM-3008; RO4948191 | ||
| RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon. RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity. | ||
| M49551 | JAK-IN-5 hydrochloride | JAK |
| JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. | ||
| M49555 | JAK-IN-11 | JAK |
| JAK-IN-11 is a potent and selective JAK inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment. | ||
| M49565 | Ilunocitinib | JAK |
| Ilunocitinib is a JAK inhibitor (extracted from patent WO2009114512A1). | ||
| M49566 | Itacnosertib | JAK |
| Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871. | ||
| M49577 | JAK1-IN-8 | JAK |
| JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1. | ||
| M49594 | JAK3-IN-7 | JAK |
| JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC50 of <0.01 μM. | ||
| M49610 | JAK-IN-5 | JAK |
| JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. | ||
| M49620 | Rovadicitinib | JAK |
| Rovadicitinib is a Janus kinase (JAK) inhibitor with an IC50 value <20 nM. | ||
| M49621 | Rovadicitinib hydrochloride | JAK |
| Rovadicitinib hydrochloride is a JAK inhibitor with an IC50 value <20 nM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
